ERBB2 and cancer: If age-based selection criteria are to be used in HR+/HER2-negative eBC, GT for BRCA germline pathogenic variants can be limited to patients aged ≤50 years at cancer diagnosis with an unknown or limited family history of cancer (or ≤45 years of age at cancer diagnosis with no family history of cancer for more restrictive patient selection if there are challenges to access GC/GT).